{"filing":{"accession_number":"0001600620-26-000066","cik":"0001600620","ticker":"AUPH","company_name":"Aurinia Pharmaceuticals Inc.","form":"8-K","filing_date":"2026-08-19","report_date":"2026-08-19","primary_document":"auph-20260819.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000066/auph-20260819.htm"},"events":[{"id":28510,"run_id":26082,"accession_number":"0001600620-26-000066","anchor_item_number":"8.01","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"summary":"Aurinia announced a settlement agreement with Teva resolving patent infringement litigation over voclosporin generic entry. The settlement stipulates validity and enforceability of two key patents expiring in December 2037 and grants Aurinia market exclusivity until December 7, 2036. This is a material litigation settlement that directly affects the company's ability to protect its lead commercial product (LUPKYNIS/voclosporin) from generic competition, a core business asset for a biopharmaceutical company.","company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","filing_date":"2026-08-19","form":"8-K","submitted_at":null,"items":[{"id":30476,"accession_number":"0001600620-26-000066","item_number":"8.01","item_title":null,"event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"reasoning":"Aurinia announced a settlement agreement with Teva resolving patent infringement litigation over voclosporin generic entry. The settlement stipulates validity and enforceability of two key patents expiring in December 2037 and grants Aurinia market exclusivity until December 7, 2036. This is a material litigation settlement that directly affects the company's ability to protect its lead commercial product (LUPKYNIS/voclosporin) from generic competition, a core business asset for a biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T20:12:42.368186+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30476,"accession_number":"0001600620-26-000066","item_number":"8.01","item_title":null,"event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"reasoning":"Aurinia announced a settlement agreement with Teva resolving patent infringement litigation over voclosporin generic entry. The settlement stipulates validity and enforceability of two key patents expiring in December 2037 and grants Aurinia market exclusivity until December 7, 2036. This is a material litigation settlement that directly affects the company's ability to protect its lead commercial product (LUPKYNIS/voclosporin) from generic competition, a core business asset for a biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T20:12:42.368186+00:00","company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","filing_date":"2026-08-19"}]}